Holen Sie sich die Stockscreener-App
4.57
1.30%
-0.06
Handel nachbörslich:
4.56
-0.01
-0.22%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$4.63
Offen:
$4.65
24-Stunden-Volumen:
2.23M
Relative Volume:
0.47
Marktkapitalisierung:
$572.31M
Einnahmen:
$409.00K
Nettoeinkommen (Verlust:
$-101.35M
KGV:
-2.7866
EPS:
-1.64
Netto-Cashflow:
$-71.49M
1W Leistung:
-7.11%
1M Leistung:
+12.84%
6M Leistung:
+26.24%
1J Leistung:
-26.53%
1-Tages-Spanne:
$4.47
$4.70
1-Wochen-Bereich:
$4.47
$5.085
52-Wochen-Spanne:
$2.90
$7.73
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
4.57 | 579.82M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Sell |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-24 | Eingeleitet | Goldman | Neutral |
| 2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-11 | Eingeleitet | Guggenheim | Buy |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-11-12 | Bestätigt | B. Riley Securities | Buy |
| 2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
| 2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
| 2019-07-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Altimmune gains on FDA breakthrough designation for MASH therapy - MSN
Altimmune, Inc. Closes $75 Million Registered Direct Offering to Advance Pemvidutide Development for Liver Diseases - Quiver Quantitative
Altimmune, Inc. (ALT) gains analyst support ahead of phase 3 MASH development - MSN
Is Altimmune Inc a strong candidate for buy and hold2025 Growth vs Value & AI Powered Market Entry Ideas - baoquankhu1.vn
Altimmune Sets 2026 Annual Stockholder Meeting Timeline - TipRanks
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 (NASDAQ:ALT) - Seeking Alpha
Forecast Cut: Is Altimmune Inc a strong candidate for buy and holdTake Profit & Smart Swing Trading Techniques - baoquankhu1.vn
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development - Insider Monkey
Growth Report: Is Altimmune Inc a strong candidate for buy and holdJuly 2025 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn
Altimmune stock price ends higher after $75 million deal closes as Vanguard filing adds focus - TechStock²
Altimmune, Inc. (ALT) Stock Analysis: Exploring a 246% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Altimmune closes $75 million registered direct offering By Investing.com - Investing.com India
Altimmune (NASDAQ:ALT) Trading Up 7.2%Here's What Happened - MarketBeat
Is Altimmune Inc. a potential multi baggerAnalyst Upgrade & High Accuracy Trade Signal Alerts - mfd.ru
Altimmune closes $75 million registered direct offering - Investing.com
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock - The Manila Times
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock - Benzinga
Biotech Altimmune raises $75M for Phase 3 MASH liver drug trial - Stock Titan
Altimmune (NASDAQ:ALT) Rating Increased to Strong-Buy at Barclays - MarketBeat
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration - Sahm
Altimmune raises $75 million to fund MASH therapy development By Investing.com - Investing.com Nigeria
ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon - Stocktwits
Altimmune Announces $75 Million Registered Direct Equity Offering - TipRanks
Altimmune Signs Multiple Material Agreements - TradingView
Altimmune: Why Breakthrough Status Isn't A 'Buy' Signal Just Yet (NASDAQ:ALT) - Seeking Alpha
Altimmune (ALT) Shares Slide On $75 Million Stock Offering - Benzinga
Altimmune prices $75M direct offering - MSN
Altimmune (NASDAQ:ALT) Shares Gap DownHere's Why - MarketBeat
Altimmune Stock Volatility Spurs Investor Attention - StocksToTrade
Altimmune’s Recent Developments and Market Impact - timothysykes.com
Altimmune shares slide after $75 million registered direct offering - MSN
Altimmune stock falls after announcing $75 million direct offering By Investing.com - Investing.com South Africa
Altimmune stock falls after announcing $75 million direct offering - Investing.com
Qorvo, Altimmune, United Microelectronics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Altimmune Prices $75 Million Registered Direct Offering - marketscreener.com
Biotech Altimmune raises $75M to prepare Phase 3 MASH liver trial - Stock Titan
Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline - TipRanks
Altimmune Prices $75 Mln Of Share Offering; Stock Down - Nasdaq
Altimmune (ALT) Prepares for Phase 3 Trial with New Funding - GuruFocus
Altimmune Secures $75M from Institutional Investor in Direct Offering - Intellectia AI
Altimmune (ALT) Secures $75M in Direct Offering to Fund Phase 3 Trial - GuruFocus
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock - The Manila Times
Trend Recap: Will Altimmune Inc stock hit new highs in YEAR - baoquankhu1.vn
Altimmune raises $75 million to fund MASH therapy development - Investing.com
Altimmune, Inc. Announces $75 Million Registered Direct Offering to Support Phase 3 Trial for Pemvidutide - Quiver Quantitative
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):